Said Sebti (Arabic: سيد سبتي, (first name (pronounced [ˈsæjjɪd]) is an American cancer researcher who is Professor and Chairman of the Department of Drug Discovery at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Fl.
Sebti is noted for his work to rehabilitate the 'failed' cancer drug Triciribine, now under development at the pharmaceutical company Prescient Therapeutics (ASX: PTX).
He then spent three years as an assistant professor at the University of Pittsburgh before joining Moffitt Cancer Center in 1996 as Director of its Drug Discovery Program.
[2] Normal cells often turn cancerous when signal transduction molecules become mutated.
[3] Prescient Therapeutics originated in 2014 from two drug discovery programmes pioneered by the Sebti lab, PTX-200 and PTX-100.